Spada, In re

Decision Date10 August 1990
Docket NumberNo. 90-1109,90-1109
Citation15 USPQ2d 1655,911 F.2d 705
PartiesIn re Lonnie T. SPADA and Joseph J. Wilczynski.
CourtU.S. Court of Appeals — Federal Circuit

James H. Laughlin, Jr., Benoit, Smith & Laughlin, Arlington, Va., argued, for appellants. With him on the brief, was Michael H. Laird, Unocal Corp., Brea, Cal., of counsel.

Fred E. McKelvey, Sol., Office of the Sol., Arlington, Va., argued, for appellee. With him on the brief, was John H. Raubitschek, Associate Sol.

Before NEWMAN and MAYER, Circuit Judges, and BROWN, District Judge. *

PAULINE NEWMAN, Circuit Judge.

The decision of the United States Patent and Trademark Office (the PTO) Board of Patent Appeals and Interferences (the Board), rejecting claims 2 through 25 and 27 through 31, all the claims at issue of Spada and Wilczynski (hereinafter Spada) patent application Serial No. 859,057, filed May 2, 1986 and entitled "Pressure Sensitive Adhesives and Manufactured Articles", is affirmed.

The Invention

The Spada invention is a pressure sensitive adhesive composition comprising a water-based latex containing a normally tacky copolymer made from specified classes and proportions of monomers and having a glass transition temperature (Tg ) 1 of 0?C or less. Claim 31 was treated by the parties as representative:

Claim 31. A pressure sensitive adhesive composition comprising a water-base latex comprising a continuous aqueous medium containing dispersed particles of a normally tacky polymer having a Tg of about 0?C. or less and comprising at least about 60 weight percent olefinically unsaturated carboxylic acid ester monomers and at least about 0.1 weight percent of at least one polymerizable functional monomer of the formula:

in which R1 is a divalent organic radical of at least 3 atoms in length, R5 and R6 are independently selected from hydrogen, hydroxy, halo, thio, amino or monovalent organic radicals, and X is -CO-R4 or -CN wherein R4 is hydrogen or a monovalent organic radical.

The Spada disclosure broadly is coextensive with claim 31. While claim 31 requires that the polymers comprise members of two general classes of monomers, Spada's specific examples illustrate polymers in which members of three general classes of monomers are present.

The first class of monomer required by Spada is an olefinically unsaturated carboxylic acid ester that is present in at least about 60 weight percent of the polymer. Representative examples show 96.5 weight percent butyl acrylate (Example 2), and a combination of 48 weight percent butyl acrylate and 48 weight percent 2-ethylhexyl acrylate (Example 11).

Spada's second required class of monomer is a "polymerizable functional monomer" present in "at least about 0.1 weight percent" of the polymer (claim 31). The illustrative examples show 1-2 weight percent acetoacetoxyethyl methacrylate (AAEMA).

Spada's specification states that preferred polymer compositions include at least about 0.1 weight percent of a third class of monomer, an olefinically unsaturated carboxylic acid. Examples are 1.5 weight percent methacrylic acid (Example 2) and 3 weight percent acrylic acid (Example 7).

All of Spada's claims require that the Tg of the claimed tacky polymers is about 0?C or less, and that the products are pressure-sensitive adhesives.

The claims were rejected as unpatentable in view of the Smith reference, United States Patent No. 3,554,987, issued January 12, 1971. The Spada disclosure and the Smith reference both show polymers of the same monomers, in overlapping ratios of components. However, the products that Smith and Spada obtain are described as quite different.

The Smith Reference

Smith describes water-based latexes containing dispersed particles of polymers made from certain classes and proportions of monomers. The polymers are used in binding agents in photographic gels and films.

In most of Smith's examples three monomers are present, as in Spada's examples. The first monomer in Smith's preferred polymers is an olefinically unsaturated carboxylic acid ester, in at least 50 percent by weight of polymer. In Smith's examples this component is illustrated, inter alia, as 75.7 molar percent butyl acrylate (Example 5), and 72.4 weight percent ethyl acrylate (Example 15).

Smith's second monomer used in preparing his preferred polymers is a polymerizable functional monomer like that described by Spada, present in about 2-20 weight percent of the polymer. Smith's examples include polymers containing 9.4 molar percent of acetoacetoxyethyl acrylate (AAEA) (Example 5), and 3.5 weight percent AAEMA (Example 15). Spada incorporated by reference the entire disclosure of the Smith patent, as showing polymerizable functional monomers suitable and preferred for use in the Spada polymers, and the preparation of these monomers.

The preferred polymers of Smith contain a third monomer, as do Spada's, and most of Smith's examples include acrylic acid. Thus, in Smith's Example 5 the complete polymer composition is 75.7 molar percent butyl acrylate, 9.4 molar percent AAEA, and 14.9 molar percent acrylic acid. In Smith's Example 15 the composition is 72.4 weight percent ethyl acrylate, 3.5 weight percent AAEMA, and 24.1 weight percent acrylic acid.

Smith states that emulsions containing his polymers have improved properties of hardness, resistance to abrasion, good adhesion, and dimensional stability. Smith does not show or suggest that his polymer latexes can form a normally tacky pressure-sensitive adhesive--properties admitted to be different from hardness and abrasion resistance.

Discussion

The Board affirmed the rejection of Spada's claims under 35 U.S.C. Secs. 102, 103, this hybrid rejection having apparently been made on the theory that if the claimed subject matter was novel, i.e. not anticipated, in terms of section 102, then it would have been obvious under section 103. 2 The Commissioner on this appeal concentrates on the rejection for anticipation. The Commissioner argues that a prima facie case 3 of anticipation is made by the Smith disclosure of polymers that are apparently identical to those of Spada, although the properties described by Smith are different from those that are reported by Spada and included as express limitations in Spada's claims.

Rejection for anticipation or lack of novelty requires, as the first step in the inquiry, that all the elements of the claimed invention be described in a single reference. Richardson v. Suzuki Motor Co., 868 F.2d 1226, 1236, 9 USPQ2d 1913, 1920 (Fed.Cir.), cert. denied, --- U.S. ----, 110 S.Ct. 154, 107 L.Ed.2d 112 (1989). Further, the reference must describe the applicant's claimed invention sufficiently to have placed a person of ordinary skill in the field of the invention in possession of it. Akzo N.V. v. United States Int'l Trade Comm'n, 808 F.2d 1471, 1479, 1 USPQ2d 1241, 1245 (Fed.Cir.1986), cert. denied, 482 U.S. 909, 107 S.Ct. 2490, 96 L.Ed.2d 382 (1987); In re Coker, 463 F.2d 1344, 1348, 175 USPQ 26, 29 (CCPA 1972).

Spada argues that Smith does not describe Spada's claimed invention, for to find anticipation "all limitations in the claims must be found in the reference since the claims measure the invention." In re Lange, 644 F.2d 856, 862, 209 USPQ 288, 293 (CCPA 1981). Spada states that since his compositions are claimed as pressure-sensitive adhesives containing a tacky polymer having a Tg below 0?C, they can not be anticipated. Spada argues that since the Smith products are hard, abrasion-resistent solids, they are ipso facto different.

The discovery of a new property or use of a previously known composition, even when that property and use are unobvious from the prior art, can not impart patentability to claims to the known composition. 4 Titanium Metals Corp. v. Banner, 778 F.2d 775, 780, 782, 227 USPQ 773, 777-78, 778 (Fed.Cir.1985); In re Pearson, 494 F.2d 1399, 1403, 181 USPQ 641, 644 (CCPA 1974); In re Lemin, 326 F.2d 437, 440, 140 USPQ 273, 276 (CCPA 1964). Thus, the initial inquiry is to the novelty of the composition. Titanium Metals, 778 F.2d at 780, 227 USPQ at 777.

The Board held that the compositions claimed by Spada "appear to be identical" to those described by Smith. While Spada criticizes the usage of the word "appear", we think that it was reasonable for the PTO to infer that the polymerization by both Smith and Spada of identical monomers, employing the same or similar polymerization techniques, would produce polymers having the identical composition. Products of identical chemical composition can not have mutually exclusive properties. See In re Papesch, 315 F.2d 381, 391, 137 USPQ 43, 51 (CCPA 1963) (a chemical compound and its properties are inseparable).

While the art and science of polymer chemistry may be distinguished from that of simpler compounds and compositions, in Spada's case we conclude that the Board correctly found that the virtual identity of monomers and procedures sufficed to support a prima facie case...

To continue reading

Request your trial
2398 cases
  • Evans Medical Ltd. v. American Cyanamid Co.
    • United States
    • United States District Courts. 2nd Circuit. United States District Courts. 2nd Circuit. Southern District of New York
    • 10 juin 1998
    ...field of the invention. Scripps Clinic & Research Found. v. Genentech, Inc., 927 F.2d 1565, 1576 (Fed.Cir.1991); accord In re Spada, 911 F.2d 705, 708 (Fed. Cir.1990) ("the reference must describe the applicant's invention sufficiently to have placed a person of ordinary skill in the field ......
  • Cedarapids, Inc. v. Nordberg, Inc.
    • United States
    • United States District Courts. 8th Circuit. Northern District of Iowa
    • 10 août 1995
    ...invention sufficiently to have placed a person of ordinary skill in the field of the invention in possession of it." In re Spada, 911 F.2d 705, 708 (Fed.Cir.1990). "When more than one reference is required to establish unpatentability of the claimed invention anticipation under ? 102 cannot......
  • Volterra Semiconductor Corp. v. Primarion, Inc.
    • United States
    • United States District Courts. 9th Circuit. United States District Courts. 9th Circuit. Northern District of California
    • 4 mai 2011
    ...invention sufficiently to have placed a person of ordinary skill in the field of the invention in possession of it.” In re Spada, 911 F.2d 705, 708 (Fed.Cir.1990). In particular, to establish anticipation under § 102(a) on the basis of a printed publication, “each and every limitation [must......
  • Merck & Co., Inc. v. Mylan Pharmaceuticals, CIVIL ACTION NO. 97-CV-4241 (E.D. Pa. 8/__/1998)
    • United States
    • United States District Courts. 3th Circuit. United States District Court (Eastern District of Pennsylvania)
    • 1 août 1998
    ...of [these amounts]." Motorola, Inc. v. Interdigital Technology Corp., 121 F.3d 1461, 1473 (Fed.Cir. 1997), citing In re Spada, 911 F.2d 705, 708 (Fed.Cir. 1990); see also Continental Can Co., 948 F.2d at 1268. More specifically, the example describes a 200 mg levodopa plus 50 mg carbidopa c......
  • Request a trial to view additional results
2 firm's commentaries
  • Obviousness In Inter Partes Review Proceedings
    • United States
    • Mondaq United States
    • 8 février 2016
    ...arts, it is well known that "[p]roducts of identical chemical composition cannot have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, (Fed. Cir. 1990). Without establishing the identity of the compositions, however, a conclusion of identical properties fails. In Ferrum Ferro......
  • Prior Art Range Encompassing The Claimed Invention Creates A Rebuttable Presumption Of Obviousness
    • United States
    • Mondaq United States
    • 2 août 2011
    ...and use are unobvious from the prior art, can not [sic] impart patentability to the known composition." Id. at 8 (quoting In re Spada, 911 F.2d 705, 708 (Fed. Cir. Second, the Federal Circuit also rejected Tyco's argument that the prior art as a whole taught away from a range of 6 to 8 mg. ......
5 books & journal articles
  • Big Data and Pharmacovigilance: Using Health Information Exchanges to Revolutionize Drug Safety
    • United States
    • Iowa Law Review No. 99-1, November 2013
    • 1 novembre 2013
    ...be interested either to try and establish their own marketing monopoly or just for defensive use. 241. Id. 242 . See, e.g. , In re Spada, 911 F.2d 705, 708 & n.4 (Fed. Cir. 1990) (noting that “a new use of a known composition . . . may be patentable as a process”). 243 . See, e.g. , In re H......
  • Chapter §7.02 Anticipation
    • United States
    • Full Court Press Mueller on Patent Law Volume I: Patentability and Validity Title CHAPTER 7 Novelty, No Loss of Right, and Priority [Pre-America Invents Act of 2011]
    • Invalid date
    ...671 F.2d 1344, 1350 (C.C.P.A. 1982)).[96] Schreiber, 128 F.3d at 1478.[97] Schreiber, 128 F.3d at 1477 (citing, inter alia, In re Spada, 911 F.2d 705, 708 (Fed. Cir. 1990) ("The discovery of a new property or use of a previously known composition, even when that property and use are unobvio......
  • Does Size Matter? Nanoscale Particle Size as an Indicator of Inherency in Nanopharmaceutical Patent Validity
    • United States
    • Georgia State University College of Law Georgia State Law Reviews No. 38-3, March 2022
    • Invalid date
    ...3.78. This example presumes no differences between the two chemical structures concerning size, function, and the like. See In re Spada, 911 F.2d 705, 708 (Fed. Cir. 1990) ("Products of identical chemical composition can not have mutually exclusive properties."); see also U.S. Pat. & Tradem......
  • CHAPTER § 3.03 Litigation Practices and Liability
    • United States
    • Full Court Press Regulation of Pharmaceutical Manufacturers Title CHAPTER 3 Intellectual Property Issues for Pharmaceutical Manufacturers
    • Invalid date
    ...35 U.S.C. §§ 102, 103 (pre-AIA).[247] See, e.g., Power Integrations, Inc. v. Lee, 797 F.3d 1318, 1323 (Fed. Cir. 2015).[248] In re Spada, 911 F.2d 705, 708 (Fed. Cir. 1990).[249] Id. at 708.[250] See, e.g., Endo Pharm. Solutions, Inc. v. Custopharm Inc., 894 F.3d 1374 (Fed. Cir. 2018).[251]......
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT